We are talking about the Russian vaccine “EpiVacCorona”, developed by the Federal Budgetary Scientific Institution “State Scientific Center for Virology and Biotechnology” Vector “of Rospotrebnadzor.
According to RIA Novosti, Uzbekistan has expressed interest in joint post-registration trials of the COVID-19 vaccine, which was developed by the Vector Center.
“Rospotrebnadzor held a videoconference meeting with the Agency for Sanitary and Epidemiological Welfare under the Ministry of Health of the Republic of Uzbekistan on the fight against the spread of the new coronavirus, including the development of a vaccine for the prevention of COVID-19,” the report says. The Uzbek side expressed interest in taking part in joint studies on the use of the vaccine after its registration “